Benefits of Nigella Sativa in Children With Beta Thalassemia Major
NCT ID: NCT02816957
Last Updated: 2017-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
80 participants
INTERVENTIONAL
2016-06-30
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major
NCT02597595
Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major
NCT02761395
Assessment of Cognitive Function, Fatigue and Health Related Quality of Life in Children With Beta Thalassemia
NCT05469230
the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children
NCT02674607
Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia
NCT02671695
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Evaluate the extent of clinical improvement, reductions in serum iron and ferritin, antioxidant status, treatment of the causes of hemolysis and other therapeutic benefits of Nigella sativa in those patient.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients receiving Nigella
40 patients in the treatment group that will receive nigella sativa powder (2 gm/day) for 3 consecutive months.
nigella sativ
nigella sativa powder (2 gm/day) for 3 consecutive months.
patients not received nigella as controls
40 patients in the control group will not receive nigella sativa and continued on the usual chelators
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nigella sativ
nigella sativa powder (2 gm/day) for 3 consecutive months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who discontinue treatment
3 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohamed Ramadan ELshanshory, prof
Role: STUDY_DIRECTOR
professor of pediatrics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine- Tanta University
Tanta, Gharbia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
30794l03l16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.